Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 4 1Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Prostate Cancer Metastatic 1Neuroendocrine Tumors 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Prednisone 54Radiotherapy 52Docetaxel 51Leuprolide 48Goserelin 47bicalutamide 45enzalutamide 30acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27Androgen Antagonists 27Flutamide 24Triptorelin Pamoate 22apalutamide 19Gonadotropin-Releasing Hormone 18Abiraterone Acetate 18abiraterone 16Radiation 15Zoledronic Acid 14Magnetic Resonance Spectroscopy 13gallium 68 PSMA-11 12Prednisolone 11luprolide acetate gel depot 10darolutamide 10cabazitaxel 9Radiosurgery 9Standard of Care 8Specimen Handling 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Estramustine 8Dexamethasone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Prostatic Neoplasms × Lutetium × Clear all
NCT06520345 2026-05-27

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
520 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡